Organon, a global healthcare company with a focus on women’s health, announced an agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine medicines Emgality® (galcanezumab) and RAYVOW™(lasmiditan) in Europe. Emgality, a humanized…
Viatris announced that, as it prepares to enter Phase 2 of its strategic plan, Doretta Mistras has been appointed CFO effective March 1, 2024, and Philippe Martin has been appointed Chief R&D Officer with immediate effect. Current Viatris CFO Sanjeev…
Roche has again been recognised as one of the most sustainable companies in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). Roche ranked third, Chugai Pharmaceuticals, a member of the Roche Group, ranked second. “We are extremely proud…
Merck known as MSD outside of the United States and Canada, announced that FDA has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death…
Pfizer today announced the successful completion of its acquisition of Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share,…
Merck Healthcare, a leading science and technology company, and the Pediatric Praziquantel Consortium today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel for the…
For the second year running, Servier has awarded the Servier Discovery Award to a Californian life sciences start-up. For the 2023 edition, Palm Therapeutics was rewarded for its innovative platform and approach in precision oncology drug development. Servier takes an…
AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will build on AstraZeneca’s expertise in respiratory…
Ashley Magargee has been appointed to the role of Chief Executive Officer of Genentech, a member of the Roche Group, effective January 1, 2024. In addition to her role as Head of US Commercial Portfolio, Magargee has been serving as…
The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation…